Sutezolid (PNU-100480) Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sutezolid (PNU-100480) / Sequella

panTB-HM, NCT05686356: A Pan-TB Regimen Targeting Host and Microbe

Recruiting

2/3

352

RoW

Sutezolid, N-acetyl cysteine, NAC, Pretomanid, Bedaquiline, Rifafour

The Aurum Institute NPC, Ludwig-Maximilians - University of Munich, Stichting Katholieke Universiteit, Wits Health Consortium (Pty) Ltd, Instituto Nacional de Saúde, Mozambique, National Institute for Medical Research, Tanzania, University of Stellenbosch, Sequella, Inc., Global Alliance for TB Drug Development

Tuberculosis

09/25

SUDOCU, NCT03959566: PanACEA Sutezolid Dose-finding and Combination Evaluation

Completed

RoW

Sutezolid, PNU-100480, Bedaquiline, Delamanid, Moxifloxacin, BDM, Midazolam oral solution

Michael Hoelscher, European and Developing Countries Clinical Trials Partnership (EDCTP), Sequella, Inc., Radboud University Medical Center, University of California, San Francisco, German Federal Ministry of Education and Research

Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis

09/22

RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Not yet recruiting

315

RoW

Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD

National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance

Pulmonary Tuberculosis

06/25

04/26

NCT05807399: PanACEA - STEP2C -01

Recruiting

270

RoW

BTZ-043, Rifampicin, Isoniazid, Pyrazinamide, Moxifloxacin

Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London

Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis

02/25

NCT05971602: Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Active, not recruiting

514

RoW

Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR)

Bill & Melinda Gates Medical Research Institute, Global Alliance for TB Drug Development, Janssen Pharmaceutica, Otsuka Pharmaceutical Co., Ltd.

Pulmonary Tuberculosis

01/25



	Diseases Companies Products Productz Mechanisms of Action Sites